SLC5A2 and atrial fibrillation: Cross-sectional or longitudinal analyses of large cardiovascular (CV) outcome trials have also yielded intriguing signals, suggesting that SGLT-2 inhibitors may be associated with reduced AF incidence or burden or improved rhythm-related outcome parameters, despite being neither antiarrhythmic agents per se nor specifically preferred for patients at higher AF risk [4].